Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013

Respiratory syncytial virus (RSV) causes seasonal respiratory infection, with hospitalization rates of up to 50% in high-risk infants. Palivizumab provides safe and effective, yet costly, immunoprophylaxis. The American Academy of Pediatrics (AAP) recommends palivizumab only for high-risk infants an...

Descripción completa

Detalles Bibliográficos
Autores principales: Artin, Ben, Pitzer, Virginia E., Weinberger, Daniel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139984/
https://www.ncbi.nlm.nih.gov/pubmed/34021214
http://dx.doi.org/10.1038/s41598-021-90107-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139984/
https://www.ncbi.nlm.nih.gov/pubmed/34021214
http://dx.doi.org/10.1038/s41598-021-90107-8

Ejemplares similares